Cystic Fibrosis Foundation - Click here for homepage
Stay Informed  |  Volunteer  |  Clinical Trials

In This Section

Quick Links

Find a Chapter


Study Name: Denufosol Inhalation Solution in People With Mild CF Lung Disease (TIGER 2)
Study Type: Interventional
Intervention Category: Restore Airway Surface Liquid
Study Sponsor: Inspire
Study Phase: 3
Recruitment Status: Trial Completed
Study Drug(s): Denufosol
Number of Participants Being Recruited: 450
Single / Multi-Center: Multi-Center
The purpose of this trial was to evaluate the safety and effectiveness of inhaled Denufosol designed to enhance the hydration and clearance of mucus in the lungs of CF patients. In people with CF, mucus builds up and clogs the lungs making breathing very difficult. The thick mucus also causes bacteria to get stuck in the airways, causing inflammation and infections that lead to lung damage. The trial will compare one dose strength of the drug, denufosol, to a placebo in patients with mild CF lung disease. Results of a previous trial have shown that patients receiving denufosol had significantly better lung function than those receiving a placebo. The drug is designed to enhance the lung's natural mucosal hydration and mucociliary clearance. The trial planned to enroll 450 CF volunteers 5 years and older.
Age: >= 5 Years
FEV1: 75 - 110 Percent Predicted
P. aeruginosa status: Not applicable
B. cepacia status: Negative
Other Primary Eligibility Requirements:

Note: Detailed eligibility criteria information may be available on If a specific trial listing for this trial is available, a link to the specific listing will be present in the "More Information" section below.
Sponsor Contact Information: Mathews, Dave
(919) 287-1202
Trial Specific Link on
Clinical Research Terms Glossary: Click here
Primary Efficacy:

This Phase 3 placebo-controlled multi-national trial in 466 CF patients, age 5 years and older (mean age 15.1 years) with mild lung function impairment evaluated 48 weeks of treatment with denufosol (60 mg inhaled three times daily) vs placebo.
The trial did not achieve statistical significance for the primary endpoint: change from baseline in FEV1 at Week 48.

Secondary Efficacy:

The three key secondary endpoints: rate of change in percent predicted FEV1 over 48 weeks, change from baseline in FEF 25%-75% at week 48, and time to first pulmonary exacerbation also did not show any statistically significant differences between treatment groups.


Study treatments were well tolerated. The most common AE was cough, which was similar in both treatment groups.


J Cyst Fibros 2012;11(6):539-549

Back to top